Calciphylaxis cutis is a life-threatening syndrome characterized by progressive and painful skin ulcerations associated with media calcification of medium-size and small cutaneous arterial vessels. It...
Comprehensive, easy-to-understand information about this condition
How we create this content →The documentation surrounding calciphylaxis cutis is limited due to its rarity and the fact that it primarily affects patients with specific underlying conditions, such as chronic kidney disease. This makes systematic clinical studies challenging. Additionally, the complexity of the condition and the lack of identified genetic factors contribute to the limited understanding of its clinical features.
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
There are currently three active clinical trials investigating potential treatments for calciphylaxis cutis. Notable orphan drugs in development include hexasodium phytate, menaquinone, and sodium thiosulfate. These drugs aim to address the underlying mechanisms of the condition. For more information on ongoing clinical trials, you can visit ClinicalTrials.gov and search for 'calciphylaxis cutis'.
Actionable guidance for navigating care for calciphylaxis cutis
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding calciphylaxis cutis is limited due to its rarity and the fact that it primarily affects patients with specific underlying conditions, such as chronic kidney disease. This makes systematic clinical studies challenging. Additionally, the complexity of the condition and the lack of identified genetic factors contribute to the limited understanding of its clinical features.
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
There are currently three active clinical trials investigating potential treatments for calciphylaxis cutis. Notable orphan drugs in development include hexasodium phytate, menaquinone, and sodium thiosulfate. These drugs aim to address the underlying mechanisms of the condition. For more information on ongoing clinical trials, you can visit ClinicalTrials.gov and search for 'calciphylaxis cutis'.
Actionable guidance for navigating care for calciphylaxis cutis
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
The documentation surrounding calciphylaxis cutis is limited due to its rarity and the fact that it primarily affects patients with specific underlying conditions, such as chronic kidney disease. This makes systematic clinical studies challenging. Additionally, the complexity of the condition and the lack of identified genetic factors contribute to the limited understanding of its clinical features.
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
There are currently three active clinical trials investigating potential treatments for calciphylaxis cutis. Notable orphan drugs in development include hexasodium phytate, menaquinone, and sodium thiosulfate. These drugs aim to address the underlying mechanisms of the condition. For more information on ongoing clinical trials, you can visit ClinicalTrials.gov and search for 'calciphylaxis cutis'.
Actionable guidance for navigating care for calciphylaxis cutis
To navigate calciphylaxis cutis, seek a specialist in dermatology with experience in vascular conditions or a nephrologist familiar with complications related to kidney disease. While there are no specific patient organizations identified, you can explore resources like the Genetic and Rare Diseases Information Center (GARD) at rarediseases.info.nih.gov for more information. Participating in clinical trials may also provide access to cutting-edge treatments and further insights into the condition.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 31, 2026
Consider asking your healthcare providers these condition-specific questions
European rare disease database
Genetic and Rare Diseases Info Center
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.